Loading...
 
Back to the list
Mediterr J Rheumatol 2021;32(2):186-7
Article Links
Rheumatic Immuno-related Adverse Events following Immunotherapy with Check-point Inhibitors: Adverse Drug Reaction, or Other?
Ciro Manzo
Authors Information

Azienda Sanitaria Locale Napoli 3 sud, Internal and Geriatric Medicine Department – Geronthorheumatological Outpatient Clinic, Poliambulatorio “Mariano Lauro”, Sant’Agnello, Naples, Italy

 

References
  1. Pagkopoulou E, Simopoulou T, Maragkouli E, Perifanou-Sotiri S, Kotsakis A, Bogdanos DP. Arthritis and myositis in a patient treated with programmed cell death-1 (PD-1) inhibitor pembrolizumab for lung cancer. Mediterr J Rheumatol 2020;31:355-7.
  2. Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2018;77:393-8.
  3. Gediz F, Kobak S. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know? Curr Rheumatol Rev 2019;15:201-8.
  4. Ramos-Casals M, Alexandre M, Suarez-Almazor ME, Lambotte O, Fisher BA, Hernandez-Molina G, et al. Sicca/Sjogren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clin Exp Rheumatol 2019;37(Suppl 118):114-22.
  5. Manzo C, Isetta M, Natale M, Castagna A. Identification and classification of polymyalgia rheumatica (PMR) and PMR-like syndromes following immune checkpoint inhibitors (ICIs) therapy : discussion points and grey areas emerging from a systematic review of published literature. Medicines (Basel) 2020;7(11):68.
  6. Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol 2019;71:468-75.
  7. Kuswanto WF, MacFarlane LA, Gedmintas L, Mulloy A, Choueiri TK, Bermas BL. Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Semin Arthritis Rheum 2018;47:907-10.  
  8. Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 2018;17:284-9.
  9. Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions. Drug Saf 2008;31:21-37.
  10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Robert EA, et al. A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther 1981;30:239-45.
  11. Kostine M, Finckh A, Bingham 3rd CO, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2020;0:1–13.
  12. Azar L, Khasnis A. Paraneoplastic rheumatologic syndromes. Curr Opin Rheumatol 2013;25:44-9. 
  13. Leipe J, Christ LA, Arnoldi AP, Mille E, Berger F, Heppt M, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 2018;4:e000714.
  14. Jamal S, Hudson M, Fifi-Mah A, Ye C. Immune-related adverse events associated with cancer immunotherapy: a review for the practicing rheumatologist. J Rheumatol 2020;47:166-75.